Journal List > Clin Exp Otorhinolaryngol > v.17(3) > 1516088638

TOOLS
Kim, Basurrah, Kim, and Kim: Surgical and Regenerative Treatment Options for Empty Nose Syndrome: A Systematic Review
Original Article

Clin Exp Otorhinolaryngol 2024;17(3):241-252.

Published online: 4 July 2024

DOI: https://doi.org/10.21053/ceo.2023.00038

Surgical and Regenerative Treatment Options for Empty Nose Syndrome: A Systematic Review

Do Hyun Kim1, Mohammed Abdullah Basurrah2, Soo Whan Kim1, Sung Won Kim1

1Department of Otolaryngology-Head and Neck Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

2Department of Surgery, College of Medicine, Taif University, Taif, Saudi Arabia

Corresponding author: Sung Won Kim Department of Otolaryngology-Head and Neck Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea Tel: +82-2-2258-6216, Fax: +82-2-535-1354 Email: kswent@catholic.ac.kr

Received 30 January 2024       Revised 21 June 2024       Accepted 4 July 2024

© 2024 by Korean Society of Otorhinolaryngology-Head and Neck Surgery

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objectives

Patients with empty nose syndrome typically experience paradoxical nasal congestion, nasal dryness, epistaxis, and suffocation. Conservative management is generally preferred for empty nose syndrome. However, some patients continue to experience persistent symptoms. When symptoms do not resolve, surgical options are considered. Therefore, we reviewed the surgical and regenerative treatment options for empty nose syndrome.

Methods

PubMed, Embase, Scopus, Cochrane Register of Controlled Trials, and Google Scholar were searched from the earliest date provided in the database until December 2022. This review included studies that assessed treatment outcomes using patient symptom scores, including the Sino-Nasal Outcome Test (SNOT-20, -22, and -25) and the Empty Nose Syndrome 6-Item Questionnaire, supplemented by various clinical examinations.

Results

Twenty-eight studies were analyzed. Various materials were utilized, including submucosal injectable materials, allografts/xenografts/cadaveric implants, autologous implants, and synthetic implants. The polyethylene implant was the most commonly used (23.3%), followed by autologous, homologous, or cadaveric costal cartilage (20%). The anterior-inferior lateral nasal wall was the most frequent site of administration. Most studies indicated that surgical intervention led to significant improvements in clinical outcomes, as evidenced by endoscopic exams, acoustic rhinometry, and computed tomography scans, along with patient-reported enhancements in nasal symptoms, psychological well-being, and overall health-related quality of life. However, several studies found no improvement in certain psychological-related questionnaires or saccharin transit times. The average follow-up duration was 12.0 months (range, 2.0–27.6 months). Only two studies reported postoperative adverse effects.

Conclusion

Several surgical options and recent tissue regeneration techniques have demonstrated efficacy in treating empty nose syndrome. However, more detailed investigations involving a larger number of participants and a randomized control study are necessary to establish a standardized treatment protocol for patients with empty nose syndrome.

Keywords: Atrophic Rhinitis, Therapeutics, Operative Surgical Procedures, Sino-Nasal Outcome Test, Review

INTRODUCTION

Empty nose syndrome is an iatrogenic disorder that develops after nasal surgery, particularly surgery on the inferior turbinates [1-3]. The term “empty nose syndrome” was coined by Kern and Stenkvist in 1994 to describe the significant loss of intranasal tissue around the inferior and middle turbinates [4]. This condition is characterized by a paradoxical sensation of nasal obstruction despite a widened nasal airway. Symptoms vary and include nasal crusting, dryness, intermittent bleeding, thick nasal discharge, facial pain, feelings of suffocation, difficulty breathing through the nose, excessive airflow, shortness of breath, and inadequate lung inflation [1,5-7]. Therefore, empty nose syndrome is associated with impaired quality of life and psychological distress. Patients may suffer from poor sleep quality, difficulty concentrating, anxiety, panic attacks, and suicidal ideation [8,9]. Many patients with empty nose syndrome are considered to have either neuropathy or rhinitis hystericus. Furthermore, the sensation of an “empty nose” is often viewed as a normal part of recovery following nasal surgery, leading to the neglect and mistreatment of these symptoms in patients with empty nose syndrome [10]. Although empty nose syndrome is traditionally managed with conservative care, recent studies suggest that surgical interventions or mucosal regenerative approaches can provide long-term symptom relief.
This systematic review examined surgical and regenerative treatment options for empty nose syndrome, compared their advantages and disadvantages, and aimed to offer valuable insights into treatment policies for patients with intractable empty nose syndrome.

MATERIALS AND METHODS

Search strategy

The Institutional Review Board of the Catholic University of Korea waived approval for this study because it is a systematic review and meta-analysis based exclusively on published literature. This study followed the population (patients with empty nose syndrome), intervention (surgery of the nasal cavity), comparison (not specified), outcomes (symptoms or endoscopic scores), and study design (not limited) framework. We searched the following electronic databases for studies published from the time the literature search was available until December 2022: PubMed, Embase, Scopus, Cochrane Register of Controlled Trials, and Google Scholar. The search terms included “empty nose syndrome,” “atrophic rhinitis,” and “treatment.” The search strategy was developed in collaboration with a librarian who had over 10 years of experience in conducting information searches. Review articles, non-human studies, and studies with missing information on materials and methods were excluded. In addition, among the literature searched for atrophic rhinitis, etiologies other than empty nose syndrome secondary to iatrogenic causes were excluded. We comprehensively reviewed the references cited in relevant studies to identify additional papers. Supplementary Table 1 presents the details of our search strategy. Fig. 1 provides an overview of the study selection process. Two reviewers (SWK and MAB) independently screened the titles and abstracts; studies that were irrelevant to the subject matter were excluded. Discrepancies between the reviewers were resolved through discussion with a third reviewer (SWK). Full-text versions of potentially eligible studies were reviewed for eligibility. The study protocol was registered on the Open Science Framework (https://osf.io/3uamv/).

Data curation and risk of bias assessment

We systematically collected data from eligible studies that met our selection criteria, including the number of patients, scale and score used for endoscopic findings, and incidence or percentage of postoperative adverse events, such as adhesions, middle turbinate lateralization, polypoid change, and need for postoperative therapeutic intervention. Data were collected in a standardized format using established forms [11-14]. Treatment measurements were evaluated using various methods, such as endoscopic exams, computed tomography, symptom scoring systems (such as the Sino-Nasal Outcome Test, Empty Nose Syndrome 6-Item Questionnaire, visual analog scale, Nasal Obstruction Symptom Evaluation, and Rhinosinusitis Quality of Life), psychological change questionnaires or overall health-related quality of life scoring questionnaires (such as the Beck Depression Inventory, Beck Anxiety Inventory, Generalized Anxiety Disorder 7-item scale, and Patient Health Questionnaire-9), saccharin transit time, acoustic rhinometry, and rhinomanometry. We evaluated the quality of the included studies using the Newcastle-Ottawa Scale. In addition, the Cochrane Risk of Bias tool was used to assess the risk of bias in randomized controlled studies.

RESULTS

Our review included 28 studies [15-42]. Tables 1 and 2 provide details on the characteristics of the included studies, while Supplementary Tables 2 and 3 present a summary of the risk of bias assessment. In both randomized controlled studies, the randomization process was judged to have “some concerns.” All nonrandomized controlled studies assessed using The Newcastle-Ottawa Scale were rated as good quality. The majority of the studies were case series and case-control studies, with only two being randomized controlled trials. Additionally, more than half of the reports (57.1%) utilized the cotton test [5,43] for pretreatment evaluation.
Several materials have been used as intranasal implants, including various autologous transplants such as dermal fat, septal, conchal, and costal cartilage. Other implants include homologous costal cartilage, acellular dermis graft (AlloDerm, LifeCell Corp.), polyethylene implant (Medpor, Porex Surgical Inc.), silastic sheet, β-tricalcium phosphate implant (Sinus-Up Implants, Kasios), and porcine small intestine submucosal xenograft (Biodesign, Cook Biomedical). Additionally, materials such as hydroxyapatite cement, carboxymethylcellulose or glycerin gel, Placentrex, hyaluronic acid, platelet-rich plasma, and autologous lipoaspirate injection formulations have been used to treat empty nose syndrome, with favorable effects reported regardless of the substance administered. Only one study, which analyzed the effects of administering platelet-rich plasma after performing submucosal diathermy, reported no significant difference in saccharin transit time between the two groups [20]. However, the effectiveness of injectable substances such as Placentrex, platelet-rich plasma, and hyaluronic acid gel injection decreases after 3–6 months.
The most common site for administration was the anterior-inferior lateral nasal wall, followed by the inferior turbinate, nasal floor, and septum. Treatment outcomes were assessed using a variety of methods, including endoscopic exams, computed tomography, symptom scoring systems, saccharin transit time, acoustic rhinometry, and rhinomanometry. Most studies reported improvements in nasal symptom scoring systems, such as the SinoNasal Outcome Test, Empty Nose Syndrome 6-Item Questionnaire, visual analog scale, Nasal Obstruction Symptom Evaluation, and Rhinosinusitis Quality of Life. Additionally, favorable outcomes were generally observed in the results of endoscopic exams, computed tomography, acoustic rhinometry, and rhinomanometry. However, the results were mixed in psychological change questionnaires or overall health-related quality of life scoring questionnaires, including the Beck Depression Inventory, Beck Anxiety Inventory, Generalized Anxiety Disorder 7-item scale, and Patient Health Questionnaire-9. The average follow-up duration was 12.0 months (range, 2.0–27.6 months). Only two studies reported postoperative adverse effects [27,31], including exposed implants and pressure sensation in the upper alveolar dentition.

DISCUSSION

Numerous nasal surgical procedures, such as inferior turbinectomy or turbinoplasty, are routinely performed in otorhinolaryngology departments. Among these procedures, a significant number of patients may develop empty nose syndrome, which shares clinical features with atrophic rhinitis [4]. In most cases, conservative treatment is the initial choice. However, some patients do not respond to treatment, and their numbers are growing annually. A study from a decade ago indicated that only up to 21% of patients showed marginal clinical improvement even after undergoing surgical treatment [44]. Despite this, more refined surgical techniques have been developed recently, and interest in regenerative treatment options has been growing [45]. Therefore, this review aimed to organize and evaluate the literature on surgical and regenerative treatment options for patients with empty nose syndrome. Although the available literature lacks randomized controlled trials, most studies have reported significant symptom improvement regardless of the treatment option used, and implantable materials have demonstrated longer-term effects compared to injectable materials.
The pathophysiology of empty nose syndrome involves decreased air resistance in the nasal cavity due to structural changes. This condition leads to non-physiological air flow (inspiratory turbulent flow) and increased drying from a rise in shearing force on the mucosal surface area [7]. These changes result in fibrosis of the submucosal tissue of the nasal mucosa and a reduction in secretory cells [46]. Surgical interventions aim to reconstruct the deformed nasal structure, maintain humidity, and reduce air flow turbulence. In this context, the cotton test [5] serves as a valuable diagnostic tool for empty nose syndrome, helping to predict surgical outcomes and identify intervention sites. The test, which is utilized in over half of the studies, involves inserting a dry cotton plug into the area of tissue loss in the nasal cavity, particularly in the caudal region of the inferior meatus. This plug helps restore the nasal structure’s size and shape, as well as the original airflow pattern. Therefore, clinicians can assess the potential for alleviating a patient’s pain. Despite enduring severe symptoms of empty nose syndrome for extended periods, some patients report a dramatic improvement in symptoms within minutes of applying the cotton plug [43].
The classical intervention for treating empty nose syndrome is known as Young’s procedure, or the modified Young’s procedure [47,48]. Other interventions aim to reduce the size of nasal passages to dimensions similar to those before surgery or injury. This reduction aids in warming and humidifying inhaled air and helps minimize the formation of turbulent flow in the widened nasal cavity, which results from airflow passing through narrow nostrils [43]. Various materials, including submucosal injectable materials, allografts/xenografts/cadaveric implants, autologous implants, and synthetic implants, are used to achieve these outcomes.
The primary advantage of submucosal injection is its ease of administration under local anesthesia, which makes it an appealing option for patients who have concerns about general anesthesia or surgery, as well as for those whose medical comorbidities complicate the use of general anesthesia. Materials that promote tissue regeneration, such as Placentrex and platelet-rich plasma, are particularly effective when administered early after nasal surgery while tissue healing is ongoing. Additionally, substances that were previously utilized for filler or vocal cord augmentation, including hyaluronic acid gel, carboxymethylcellulose, and glycerin gel, have been employed to alleviate symptoms of empty nose syndrome, with benefits lasting between 2 and 12 months.
An acellular dermis graft (AlloDerm) and a porcine small intestine submucosal xenograft (Biodesign) have been designed to integrate into the implanted tissue over time. Cadaveric ribs, along with decellularized and irradiated tissues, carry a low risk of inflammatory reactions [38]. Although these materials can reduce the morbidity of harvesting autografts, they are relatively expensive.
Autologous cartilage is highly biocompatible and carries the lowest risk of an inflammatory response following transplantation. Septal, auricular, and costal cartilages are all potential sources for autologous cartilage grafts. However, septal cartilage is less commonly used due to the risk of inducing empty nose syndrome, a condition often associated with septoturbinoplasty. While conchal cartilage is frequently utilized for auricular cartilage grafts, costal cartilage is preferred in the treatment of empty nose syndrome because of its thickness and ease of insertion [22]. Additionally, costal cartilage enables the harvesting of a large quantity, making it ideal for addressing the total defect of the inferior turbinate. Consequently, it is extensively used in research involving autologous cartilage. Nevertheless, the extraction of costal cartilage can lead to donor-site morbidities, such as pneumothorax and chest wall deformities [49]. In such cases, homologous (cadaveric) costal cartilage is an alternative.
In addition to autologous and allolgeneic grafts, synthetic implants are also employed in the treatment of empty nose syndrome. Porous polyethylene, commonly known as Medpor, is the most frequently used implant. Other alternatives include silicone sheets, hydroxyapatite cement, and β-tricalcium phosphate implants (Sinus-Up Implants). Synthetic implants are cost-effective and simple to manipulate. However, they are associated with a relatively high risk of complications, such as foreign body reactions, extrusion, and infection. Implant formulations demonstrated more long-lasting effects than injectable formulations. However, due to the delicate and sensitive nature of the nasal mucosa, implanted materials may become exposed or cause pain following insertion. Conversely, injectable materials carry a risk of causing ophthalmic complications, though such incidents are extremely rare [50,51].
Recent advancements in cell-based organoid technologies and tissue engineering have facilitated the development of mucosal tissue regeneration using stem cells and scaffolds that sustain this effect [45,52]. Additionally, there have been reports of human turbinate-derived stem cells being applied to scaffolds in both three-dimensional printed and spheroid forms, serving as a niche for mucosal regeneration [52-54]. These advancements are expected to integrate the benefits of both injectable and implant formulations, offering a potential solution to the limitations inherent to each method.
This study has several limitations. The majority of the studies reviewed in this manuscript were heterogeneous case series or case-control studies, which did not allow for a direct comparison of interventions. Additionally, some reports lacked detailed descriptions of the main procedures and potential adverse effects. The heterogeneity and insufficient data precluded the possibility of conducting a meta-analysis to ascertain the effects. A significant limitation in assessing the symptoms and severity of empty nose syndrome is the absence of standardized diagnostic criteria specific to the condition. Recently, questionnaires such as the ENSQ-6 have demonstrated potential in more accurately addressing empty nose syndrome, yet they require further validation. The development of standardized assessment tools for empty nose syndrome is crucial for comparing treatment methods and evaluating the efficacy of new interventions.
Various surgical modalities, along with tissue regeneration methodologies, have shown favorable outcomes in managing empty nose syndrome. These methods have improved the structural changes in the nasal cavity and have positively impacted patients’ scores on nasal symptom-, psychological-, or overall health-related quality of life questionnaires. However, there is a need to establish a standardized protocol for assessing patients with empty nose syndrome and conduct well-designed clinical investigations in order to address the unmet gaps in exploring optimal treatment options for these patients.

HIGHLIGHTS

▪ The main goal of surgery for empty nose syndrome is to restore the normal nasal airflow, thereby relieving the severe discomfort in nasal breathing in affected patients.
▪ Selection of the appropriate surgical options and grafting materials should be customized, with careful consideration of the patient’s symptoms and nasal anatomy.
▪ Tissue regeneration techniques could be cautiously considered to aid in the treatment of empty nose syndrome patients; however, future research is needed to elucidate this possibility given the limited number of existing studies.

Notes

Do Hyun Kim is an editorial board member of the journal but was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.

AUTHOR CONTRIBUTIONS

Conceptualization: DHK, SWK, SWK. Data curation: DHK, MAB, SWK (Sung Won Kim). Writing–original draft: DHK. Writing–review & final editing: all authors.

ACKNOWLEDGMENTS

This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (RS-2023-00209494, 2019M3E5D5064110), and a Korean Fund for Regenerative Medicine (KFRM) grant funded by the Korean government (23C0121L1).

SUPPLEMENTARY MATERIALS

Supplementary materials can be found online at https://doi.org/10.21053/ceo.2023.00038.
Supplementary Table 1.
Search strategy
ceo-2023-00038-Supplementary-Table-1.pdf
Supplementary Table 2.
Quality assessment of randomized controlled studies
ceo-2023-00038-Supplementary-Table-2.pdf
Supplementary Table 3.
Quality assessment of non-randomized controlled studies
ceo-2023-00038-Supplementary-Table-3.pdf
SUPPLEMENTARY REFERENCES
ceo-2023-00038-Supplementary-References.pdf

REFERENCES

1. Coste A, Dessi P, Serrano E. Empty nose syndrome. Eur Ann Otorhinolaryngol Head Neck Dis. 2012; Apr. 129(2):93–7.
2. Hong HR, Jang YJ. Correlation between remnant inferior turbinate volume and symptom severity of empty nose syndrome. Laryngoscope. 2016; Jun. 126(6):1290–5.
3. Talmadge J, Nayak JV, Yao W, Citardi MJ. Management of postsurgical empty nose syndrome. Facial Plast Surg Clin North Am. 2019; Nov. 27(4):465–75.
4. Moore EJ, Kern EB. Atrophic rhinitis: a review of 242 cases. Am J Rhinol. 2001; Nov-Dec. 15(6):355–61.
5. Chhabra N, Houser SM. The diagnosis and management of empty nose syndrome. Otolaryngol Clin North Am. 2009; Apr. 42(2):311–30.
6. Houser SM. Empty nose syndrome associated with middle turbinate resection. Otolaryngol Head Neck Surg. 2006; Dec. 135(6):972–3.
7. Scheithauer MO. Surgery of the turbinates and “empty nose” syndrome. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2010; 9:Doc03.
8. Gill AS, Said M, Tollefson TT, Steele TO. Update on empty nose syndrome: disease mechanisms, diagnostic tools, and treatment strategies. Curr Opin Otolaryngol Head Neck Surg. 2019; Aug. 27(4):237–42.
9. Li C, Farag AA, Maza G, McGhee S, Ciccone MA, Deshpande B, et al. Investigation of the abnormal nasal aerodynamics and trigeminal functions among empty nose syndrome patients. Int Forum Allergy Rhinol. 2018; Mar. 8(3):444–52.
10. Payne SC. Empty nose syndrome: what are we really talking about. Otolaryngol Clin North Am. 2009; Apr. 42(2):331–7.
11. Kim DH, Kim SW, Basurrah MA, Hwang SH. Clinical and laboratory features of various criteria of eosinophilic chronic rhinosinusitis: a systematic review and meta-analysis. Clin Exp Otorhinolaryngol. 2022; Aug. 15(3):230–46.
12. Hwang SH, Kim SW, Basurrah MA, Kim DH. Efficacy of steroid-impregnated spacers after endoscopic sinus surgery in chronic rhinosinusitis: a systematic review and meta-analysis. Clin Exp Otorhinolaryngol. 2023; May. 16(2):148–58.
13. Kim DH, Kim SW, Stybayeva G, Lim SY, Hwang SH. Predictive value of olfactory and taste symptoms in the diagnosis of COVID-19: a systematic review and meta-analysis. Clin Exp Otorhinolaryngol. 2021; Aug. 14(3):312–20.
14. Kim DH, Lee J, Kim SW, Hwang SH. The efficacy of hypotensive agents on intraoperative bleeding and recovery following general anesthesia for nasal surgery: a network meta-analysis. Clin Exp Otorhinolaryngol. 2021; May. 14(2):200–9.
15. Rice DH. Rebuilding the inferior turbinate with hydroxyapatite cement. Ear Nose Throat J. 2000; Apr. 79(4):276–7.
16. Houser SM. Surgical treatment for empty nose syndrome. Arch Otolaryngol Head Neck Surg. 2007; Sep. 133(9):858–63.
17. Jaswal A, Jana AK, Sikder B, Nandi TK, Sadhukhan SK, Das A. Novel treatment of atrophic rhinitis: early results. Eur Arch Otorhinolaryngol. 2008; Oct. 265(10):1211–7.
18. Jang YJ, Kim JH, Song HY. Empty nose syndrome: radiologic findings and treatment outcomes of endonasal microplasty using cartilage implants. Laryngoscope. 2011; Jun. 121(6):1308–12.
19. Modrzynski M. Hyaluronic acid gel in the treatment of empty nose syndrome. Am J Rhinol Allergy. 2011; Mar-Apr. 25(2):103–6.
20. Salaheldin AH, Hussein A. Effect of platelet-rich plasma on nasal mucociliary clearance after submucous diathermy of inferior turbinate. Egypt J Ear Nose Throat Allied Sci. 2012; Jul. 13(2):71–5.
21. Jiang C, Shi R, Sun Y. Study of inferior turbinate reconstruction with Medpor for the treatment of empty nose syndrome. Laryngoscope. 2013; May. 123(5):1106–11.
22. Jung JH, Baguindali MA, Park JT, Jang YJ. Costal cartilage is a superior implant material than conchal cartilage in the treatment of empty nose syndrome. Otolaryngol Head Neck Surg. 2013; Sep. 149(3):500–5.
23. Saafan ME. Acellular dermal (AlloDerm) grafts versus silastic sheets implants for management of empty nose syndrome. Eur Arch Otorhinolaryngol. 2013; Feb. 270(2):527–33.
24. Friji MT, Gopalakrishnan S, Verma SK, Parida PK, Mohapatra DP. New regenerative approach to atrophic rhinitis using autologous lipoaspirate transfer and platelet-rich plasma in five patients: our experience. Clin Otolaryngol. 2014; Oct. 39(5):289–92.
25. Jiang C, Wong F, Chen K, Shi R. Assessment of surgical results in patients with empty nose syndrome using the 25-item Sino-Nasal Outcome Test Evaluation. JAMA Otolaryngol Head Neck Surg. 2014; May. 140(5):453–8.
26. Tam YY, Lee TJ, Wu CC, Chang PH, Chen YW, Fu CH, et al. Clinical analysis of submucosal Medpor implantation for empty nose syndrome. Rhinology. 2014; Mar. 52(1):35–40.
27. Bastier PL, Fierens S, Champel S, Ribadeau-Dumas A, de Gabory L. ß-Tricalcium phosphate implants in the surgical treatment of empty nose syndrome. Otolaryngol Head Neck Surg. 2016; Sep. 155(3):514–7.
28. Velasquez N, Thamboo A, Habib AR, Huang Z, Nayak JV. The Empty Nose Syndrome 6-Item Questionnaire (ENS6Q): a validated 6-item questionnaire as a diagnostic aid for empty nose syndrome patients. Int Forum Allergy Rhinol. 2017; Jan. 7(1):64–71.
29. Lee TJ, Fu CH, Wu CL, Lee YC, Huang CC, Chang PH, et al. Surgical outcome for empty nose syndrome: impact of implantation site. Laryngoscope. 2018; Mar. 128(3):554–9.
30. Park MJ, Jang YJ. Successful management of primary atrophic rhinitis by turbinate reconstruction using autologous costal cartilage. Auris Nasus Larynx. 2018; Jun. 45(3):613–6.
31. Borchard NA, Dholakia SS, Yan CH, Zarabanda D, Thamboo A, Nayak JV. Use of intranasal submucosal fillers as a transient implant to alter upper airway aerodynamics: implications for the assessment of empty nose syndrome. Int Forum Allergy Rhinol. 2019; Jun. 9(6):681–7.
32. Thamboo A, Dholakia SS, Borchard NA, Patel VS, Tangbumrungtham N, Velasquez N, et al. Inferior meatus augmentation procedure (IMAP) to treat empty nose syndrome: a pilot study. Otolaryngol Head Neck Surg. 2020; Mar. 162(3):382–5.
33. Chang CF. Using platelet-rich fibrin scaffolds with diced cartilage graft in the treatment of empty nose syndrome. Ear Nose Throat J. 2024; Mar. 103(3):NP168–72.
34. Chang FY, Fu CH, Lee TJ. Outcomes of olfaction in patients with empty nose syndrome after submucosal implantation. Am J Otolaryngol. 2021; Jul-Aug. 42(4):102989.
35. Dholakia SS, Yang A, Kim D, Borchard NA, Chang MT, Khanwalkar A, et al. Long-term outcomes of inferior meatus augmentation procedure to treat empty nose syndrome. Laryngoscope. 2021; Nov. 131(11):E2736–41.
36. Huang CC, Wu PW, Fu CH, Huang CC, Chang PH, Lee TJ. Impact of psychologic burden on surgical outcome in empty nose syndrome. Laryngoscope. 2021; Mar. 131(3):E694–701.
37. Kim DH, Lee MH, Lee J, Song EA, Kim SW, Kim SW. Platelet-rich plasma injection in patients with atrophic rhinitis. ORL J Otorhinolaryngol Relat Spec. 2021; 83(2):104–11.
38. Malik J, Dholakia S, Spector BM, Yang A, Kim D, Borchard NA, et al. Inferior meatus augmentation procedure (IMAP) normalizes nasal airflow patterns in empty nose syndrome patients via computational fluid dynamics (CFD) modeling. Int Forum Allergy Rhinol. 2021; May. 11(5):902–9.
39. Chang MT, Bartho M, Kim D, Tsai EF, Yang A, Dholakia SS, et al. Inferior meatus augmentation procedure (IMAP) for treatment of empty nose syndrome. Laryngoscope. 2022; Jun. 132(6):1285–8.
40. Hosokawa Y, Miyawaki T, Omura K, Akutsu T, Kimura R, Ikezono T, et al. Surgical treatment for empty nose syndrome using autologous dermal fat: evaluation of symptomatic improvement. Ear Nose Throat J. 2022; Sep. 1455613221130885.
41. Huang CC, Wu PW, Lee CC, Huang CC, Fu CH, Chang PH, et al. Comparison of SNOT-25 and ENS6Q in evaluating patients with empty nose syndrome. Laryngoscope Investig Otolaryngol. 2022; Feb. 7(2):342–8.
42. Ushio M, Ishimaru J, Omura S, Ohta Y, Suzuki M. Nasal floor augmentation for empty nose syndrome. Acta Otolaryngol Case Rep. 2022; Dec. 7(1):1–7.
43. Malik J, Thamboo A, Dholakia S, Borchard NA, McGhee S, Li C, et al. The cotton test redistributes nasal airflow in patients with empty nose syndrome. Int Forum Allergy Rhinol. 2020; Apr. 10(4):539–45.
44. Leong SC. The clinical efficacy of surgical interventions for empty nose syndrome: a systematic review. Laryngoscope. 2015; Jul. 125(7):1557–62.
45. Gordiienko IM, Gubar OS, Sulik R, Kunakh T, Zlatskiy I, Zlatska A. Empty nose syndrome pathogenesis and cell-based biotechnology products as a new option for treatment. World J Stem Cells. 2021; Sep. 13(9):1293–306.
46. Wu CL, Fu CH, Lee TJ. Distinct histopathology characteristics in empty nose syndrome. Laryngoscope. 2021; Jan. 131(1):E14–8.
47. el Kholy A, Habib O, Abdel-Monem MH, Abu Safia S. Septal mucoperichondrial flap for closure of nostril in atrophic rhinitis. Rhinology. 1998; Dec. 36(4):202–3.
48. Lobo CJ, Hartley C, Farrington WT. Closure of the nasal vestibule in atrophic rhinitis: a new non-surgical technique. J Laryngol Otol. 1998; Jun. 112(6):543–6.
49. Moon BJ, Lee HJ, Jang YJ. Outcomes following rhinoplasty using autologous costal cartilage. Arch Facial Plast Surg. 2012; May-Jun. 14(3):175–80.
50. Hwang SH, Kim DH, Nam BM, Mun JY, Seong YH, Kim SW. Efficacy and safety of lyophilized articular cartilage matrix as an injectable facial filler. Aesthetic Plast Surg. 2021; Jun. 45(3):1266–72.
51. Moss WJ, Kjos KB, Karnezis TT, Lebovits MJ. Intranasal steroid injections and blindness: our personal experience and a review of the past 60 years. Laryngoscope. 2015; Apr. 125(4):796–800.
52. Kim DH, Kim SW. Clinical applications of human nasal organoids. Clin Exp Otorhinolaryngol. 2022; Aug. 15(3):201–2.
53. Lim MH, Shin S, Park K, Park J, Kim SW, Basurrah MA, et al. Deep learning model for predicting airway organoid differentiation. Tissue Eng Regen Med. 2023; Dec. 20(7):1109–17.
54. Park JH, Park JY, Nam IC, Hwang SH, Kim CS, Jung JW, et al. Human turbinate mesenchymal stromal cell sheets with bellows graft for rapid tracheal epithelial regeneration. Acta Biomater. 2015; Oct. 25:56–64.

Fig. 1.
Study selection process.
ceo-2023-00038f1.tif
Table 1.
Characteristics of the included studies
Study Study design No. of patients Sex (male: female) Age (yr) Cases/controls (n) Nation Previous surgical history Preoperative assessment Intervention Anesthesia Location Treatment outcomes Result Follow-up (mo)
Jang et al. (2011) [18] Case-control 17 11:6 41.4±15.0 (20–66) Treatment, 14/normal side, 14 Korea NA - Septal, conchal, autologous, or homologous costal cartilage (Tutoplast-processed costal cartilage, Tutogen Medical) G/A Nasal floor CT, VAS Significant improvement in nasal mucosa thickness (CT) and VAS 11.8 (6–27)
Jung et al. (2013) [22] Case-control 31 22:9 43.5 (29–57) Conchal, n=17/costal, 14 cartilage Korea NA - Conchal cartilage, costal cartilage (autologous/homologous: Tutoplast-processed costal cartilage; Tutogen Medical) G/A Anterior-inferior lateral nasal wall SNOT-25 Conchal cartilage and costal cartilage were both effective, but costal cartilage was more effective 6.9±2.0
Park et al. (2018) [30] Case report 1 0:1 63 NA Korea NA - Autologous costal cartilage G/A Anterior-inferior lateral nasal wall SNOT-25 Significant improvement in SNOT-25 24
Malik et al. (2021) [38] Case series 6 3:3 51.6±22.8 NA USA NA Cotton test Cadaveric cost cartilage NA Anterior-inferior lateral nasal wall ENS6Q, computational fluid dynamics Significant improvement in ENS6Q, restoration of nasal airflow to the inferior meatus (computational fluid dynamics) 7
Dholakia et al. (2021) [35] Case series 17 8:9 52.1±13.2 NA USA NA Cotton test, menthol test Packaged, decellularized, and irradiated segments of cadaveric rib cartilage G/A Anterior-inferior lateral nasal wall ENS6Q, SNOT-22, GAD-7, PHQ-9 Significant improvement in ENS6Q and SNOT-22 12
GAD-7 and PHQ-9 were not improved
Chang et al. (2021) [34] Case report 2 2:0 NA NA Taiwan NA Cotton test Platelet-rich fibrin scaffolds embedded with a diced cartilage graft G/A Anterior-inferior lateral nasal wall ENS6Q, endoscopic exam Significant improvement in ENS6Q; the implant was well positioned after 12 months 12
Chang et al. (2022) [39] Case series NA NA NA NA USA NA Cotton test Irradiated cadaveric rib (MTF Biologics) G/A Anterior-inferior lateral nasal wall ENS6Q, SNOT-22, GAD-7, PHQ-9 Improvement in ENS6Q, SNOT-22, GAD-7, and PHQ-9 6
Ushio et al. (2022) [42] Case series 6 5:1 NA NA Japan Partial turbinectomy Cotton test Autologous auricular cartilage G/A Nasal floor ENS6Q, SNOT-20, SNOT-25, rhinomanometry Improvement in ENS6Q, SNOT-20, SNOT-25, and rhinomanometry 14.8±4.8
Hosokawa et al. (2022) [40] Case series 9 8:1 32.22 (18–72) NA Japan NA Cotton test Autologous dermal fat G/A Nasal floor ENS6Q Improvement in ENS6Q 9.6±5.0
Houser et al. (2007) [16] Case series 8 7:1 18–45 NA USA NA Cotton test Acellular dermis graft (AlloDerm, LifeCell) G/A IT, nasal septum, floor, vestibule SNOT-20 Significant improvement in SNOT-20 27.6±15.5
Velasquez et al. (2018) [28] Case series NA NA NA NA USA NA Cotton test Porcine small intestine submucosal xenograft (Biodesign, Cook Biomedical) G/A Anterior-inferior lateral nasal wall SNOT-25 Significant improvement in SNOT-25 4
Thamboo et al. (2020) [32] Case series 10 11:3 43.5±12.1 NA USA Turbinectomy/turbinoplasty Cotton test Porcine small intestine submucosal xenograft (Biodesign, Cook Biomedical), acellular dermal graft (AlloDerm, LifeCell) NA Anterior-inferior lateral ENS6Q, SNOT-22, GAD-7, PHQ-9 Significant improvement in ENS6Q, SNOT-22, GAD-7, and PHQ-9 6
Jiang et al. (2013) [21] Case series 19 15:4 32.2 (18–64) NA China Partial/total turbinectomy Polyethylene implant (Medpor, Porex Surgical Inc.) L/A IT Acoustic rhinometry, saccharin transit time, SNOT-20 Significant improvement in SNOT-20 and acoustic rhinometry 12
Tam et al. (2014) [26] Case series 16 10:6 49.1±10.7 NA Taiwan NA Cotton test Polyethylene implant (Medpor, Porex Surgical Inc.) L/A Nasal septum, floor SNOT-22 Significant improvement in SNOT-22 12
Jiang et al. (2014) [25] Case series 24 18:6 32.4 (18–64) NA China Partial/total turbinectomy Polyethylene implant (Medpor, Porex Surgical Inc.) L/A Anterior-inferior lateral nasal wall SNOT-25 Significant improvement in SNOT-25 10.5 (3–24)
Lee et al. (2018) [29] Case-control 30 19:11 NA Lateral, 16/inferior, 14 nasal wall Taiwan Turbinectomy Cotton test Polyethylene implant (Medpor, Porex Surgical Inc.) L/A Anterior-inferior lateral nasal wall SNOT-22, BDI-II, BAI Significant improvement (more improved in lateral implants) in SNOT-22, BDI-II, and BAI 12
Huang et al. (2021) [36] Case series 54 36:18 50.9±12.2 NA Taiwan NA Cotton test Polyethylene implant (Medpor, Porex Surgical Inc.) L/A Anterior-inferior lateral nasal wall SNOT-25, BDI-II, BAI Significant improvement in SNOT-25, BDI-II, and BAI 12
Chang (2024) [33] Case series 40 31:9 49.6 (23–67) Hyposmia, 10/normosmia, 30 Taiwan Partial/total turbinectomy Cotton test, menthol test Polyethylene implant (Medpor, Porex Surgical Inc.) L/A Anterior-inferior lateral nasal wall Sniffin’ Sticks 12-items odor identification test (Burghart Instruments, Wedel) Significant improvement in olfaction in hyposmia group; no significant difference in normosmia group 6
Huang et al. (2022) [41] Case series 74 54:20 50.0±12.3 NA Taiwan NA Cotton test Polyethylene implant (Medpor, Porex Surgical Inc.) L/A Anterior-inferior lateral nasal wall ENS6Q, SNOT-25, BDI-II, BAI Significant improvement in ENS6Q and SNOT-25 6
BDI-II and BAI were not improved.
Bastier et al. (2016) [27] Case series 14 9:5 45.6±8.5 NA France Turbinectomy/turbinoplasty - β-Tricalcium phosphate implant (Sinus-Up Implants; Kasios) G/A Lateral nasal floor NOSE, RhinoQOL Significant improvement in NOSE, RhinoQOL 19.4±13.4
Saafan et al. (2013) [23] Case-control 24 11:13 27±10 Silastic sheet, 12/acellular dermal graft, 12 Egypt NA Cotton test Silastic sheet, acellular dermal graft (AlloDerm, LifeCell) G/A Anterior-inferior lateral nasal wall, nasal septum, floor SNOT-25 Significant improvement in SNOT-25 in both groups 18 (9–24)
Rice (2000) [15] Case report 1 0:1 42 NA USA Complete turbinectomy - Hydroxyapatite cement NA Anterior-inferior lateral nasal wall Endoscopic exam Holds up well after 1 year 12
Modrzynski (2011) [19] Case series 3 1:2 56.3±8.0 NA USA NA - Hyaluronic acid gel (Juvéderm, Allergan Inc.) L/A IT, nasal septum Endoscopic exam Hyaluronic acid was maintained for up to 6 months, but all except one case (33.3%) showed absorption at 12 months. 12
Borchard et al. (2019) [31] Case series 14 10:4 44.6±13.8 NA USA NA Cotton test Carboxymethylcellulose/glycerin gel (Prolaryn, Merz) L/A Anterior-inferior lateral nasal wall ENS6Q, SNOT-22, GAD-7, PHQ-9 Maximum effect after 1 week of administration; decreased effect after 1 or 3 months (ENS6Q, SNOT-22, PHQ-9); maintained up to 3 months after maximal effect after 1 month of administration (GAD-7) 3
Jaswal et al. (2008) [17] Randomized controlled trial 30 NA 28.3 (18–51) Placentrex injection, 10/oral rifampicin, 10/control, 10 India NA - Placentrex injection NA NA Endoscopic exam, patient symptom score In the Placentrex injection group, symptoms recurred at an average of 2.7 months. 4
Salaheldin et al. (2012) [20] Randomized controlled trial 60 36:24 31.5 (18–50) Submucosal diathermy with, 15 or without, 15 platelet-rich plasma Egypt Turbinoplasty (submucosal diathermy) - Platelet-rich plasma injection G/A IT Saccharin transit time No differences between the two groups 2
Friji et al. (2014) [24] Case series 5 2:3 NA NA India NA - Autologous lipoaspirate with platelet-rich plasma injection NA IT SNOT-20, saccharin transit time Significant improvement in SNOT-20 and saccharin transit time 6
Kim et al. (2021) [37] Case-control 22 19:3 53.3±12.1 Platelet-rich plasma/saline spray Korea NA - Platelet-rich plasma injection L/A IT NOSE, SNOT-22, saccharin transit time Significant improvement in NOSE and SNOT-22. The saccharin transit time slowed down again after maximal effect at 2 months of administration. 6

Values are presented as mean±SD (range), median (range), or mean±SD.

NA, not available; G/A, general anesthesia; CT, computed tomography; VAS, visual analog scale; SNOT, Sino-Nasal Outcome Test; ENS6Q, Empty Nose Syndrome 6-Item Questionnaire; GAD-7, Generalized Anxiety Disorder 7-item scale; PHQ-9, Patient Health Questionnaire-9; IT, inferior turbinate; L/A, local anesthesia; BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory; NOSE, Nasal Obstruction Symptom Evaluation; RhinoQOL, Rhinosinusitis Quality of Life; SD, standard deviation.

Table 2.
Summary of patient-reported outcome measurements
Study Assessment tool (min–max) Pre–post mean differences (SD)
Jang et al. (2011) [18] VAS (0–10) Excessive airflow: 6.2 (3.6)
Nasal obstruction: 5.0 (3.3)
Nasal or facial pain: 6.0 (3.7)
Rhinorrhea or postnasal drip: 2.3 (4.7)
Headache: 8.5 (2.1)
Jung et al. (2013) [22] SNOT-25 (0–125) Conchal cartilage: 18.1
Costal cartilage: 21.9
Park et al. (2018) [30] SNOT-25 (0–125) 102
Malik et al. (2021) [38] ENS6Q (0–30) 9.2 (4.9)
Dholakia et al. (2021) [35] ENS6Q (0–30) ENS6Q: 10.3
SNOT-22 (0–110) SNOT-22: 17.4
GAD-7 (0–21) GAD-7: 2.3
PHQ-9 (0–27) PHQ-9: 2.8
Chang et al. (2021) [34] ENS6Q (0–30) 15
Ushio et al. (2022) [42] ENS6Q (0–30) ENS6Q: 18.6
SNOT-20 (0–100) SNOT-20: 24.9
SNOT-25 (0–125) SNOT-25: 8.3
Hosokawa et al. (2022) [40] ENS6Q (0–30) 15.7 (8.2)
Houser et al. (2007) [16] SNOT-20 (0–100) 20.4 (24.1)
Velasquez et al. (2018) [28] SNOT-25 (0–125) 22.6 (15.8)
Thamboo et al. (2020) [32] ENS6Q (0–30) ENS6Q: 13.3
SNOT-22 (0–110) SNOT-22: 31.2
GAD-7 (0–21) GAD-7: 9.5
PHQ-9 (0–27) PHQ-9: 8.3
Jiang et al. (2013) [21] SNOT-20 (0–100) 12.4 (20.2)
Tam et al. (2014) [26] SNOT-22 (0–110) 23.1 (0.8)
Jiang et al. (2014) [25] SNOT-25 (0–125) 40.6 (28.1)
Lee et al. (2018) [29] SNOT-22 (0–110) Inferior nasal wall: 19.6 (33.1)
Lateral nasal wall: 37.5 (29.0)
Huang et al. (2021) [36] SNOT-25 (0–125) SNOT-25: 34.7 (34.3)
BDI-II (0–63) BDI-II: 12.9 (18.7)
BAI (0–63) BAI: 6.5 (13.3)
Chang (2024) [33] Sniffin’ Sticks 12-item odor identification test (Burghart Instruments) (0–12) Hyposmia: –1.1 (1.1)
Normosmia: –0.1 (0.1)
Huang et al. (2022) [41] ENS6Q (0–30) ENS6Q: 8.4 (7.4)
SNOT-25 (0–125) SNOT-25: 33.1 (32.0)
BDI-II (0–63) BDI-II: 12.0 (17.2)
BAI (0–63) BAI: 9.5 (16.3)
Bastier et al. (2016) [27] NOSE (0–100) NOSE: 39.3 (36.0)
RhinoQoL (0–100) RhinoQoL: 32.7 (33.0)
Saafan et al. (2013) [23] SNOT-25 Silastic implant group: 38.8 (11.5)
AlloDerm implant group: 33.8 (17.0)
Borchard et al. (2019) [31] ENS6Q (0–30) ENS6Q: 5.3 (14.0)
SNOT-22 (0–110) SNOT-22: 11.0 (40.5)
GAD-7 (0–21) GAD-7: 3.6 (15.6)
PHQ-9 (0–27) PHQ-9: 3.7 (16.1)
Friji et al. (2014) [24] SNOT-20 (0–100) 28.0 (7.2)
Kim et al. (2021) [37] NOSE (0–100) NOSE: 12.3 (53.7)
SNOT-22 (0–110) SNOT-22: 9.4 (62.8)

Post-treatment values were calculated based on the final time point. Measurable study data are listed.

SD, standard deviation; VAS, visual analog scale; SNOT, Sino-Nasal Outcome Test; ENS6Q, Empty Nose Syndrome 6-Item Questionnaire; GAD-7, Generalized Anxiety Disorder 7-item scale; PHQ-9, Patient Health Questionnaire-9; BDI, Beck Depression Inventory; BAI, Beck Anxiety Inventory; NOSE, Nasal Obstruction Symptom Evaluation; RhinoQoL, Rhinosinusitis Quality of Life.

TOOLS
Similar articles